on the HUNT for the Next DIAMOND in the ROUGH
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A prime example of a successful strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.
As we further carve-out our position as the partner of choice for any MANF-based product development effort, we expect that we will be successful in attracting the necessary financial commitments to move MANF into clinical testing based upon the success of experiments already underway. As we continue to show progress in Parkinson's disease, we will likely be in a good negotiating position with potential partners seeking to commercialize MANF both in Parkinson's and other medical conditions, which could create multiple partnering opportunities for the Company.
the real value of this company will soon be here!
.30 is realistic for this Co
$AMBS Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion
http://www.jbc.org/content/early/2012/05/29/jbc.M112.356345
Amarantus giving Fox, other Parkinsons sufferers new hope
SUNNYVALE, CA – When NBC made a 22-show series commitment in August to actor Michael J. Fox for a series to begin airing in 2013, it was an indication of the new hope for treatment of the Parkinson's disease which forced him from regular series television a dozen years ago.
Dr. John Commissiong presents scientific findings on MANF
Dr. John Commissiong presents scientific findings on MANF
Among the 50 Most Important African-Americans in Technology
One of the big reasons for that hope is a father-son team that created Amarantus BioSciences four years ago
http://www.blackmoney.com/35117
Parkinsons is just the tip of the iceberg MANF has been shown to help with many other neurogical disorders as well. The key is the test to find early detection of these killers. Amarantus already has one for parkinsons and now onto Alzheimer's. With just these two alone...the market is HUGE If you do a little DD on MANF you will be amazed.
I feel grateful to be an investor in this Breakthrough Technology and Amarantus owns U.S and European to this compound which repairs cells that are dying when you have these conditions
"We are excited to represent Amarantus and be given the opportunity to bring value-added services to the table for our new client. Our team of experienced attorneys is impressed with the Company's proprietary technology and approach to treating Parkinson's disease and Traumatic Brain Injury," said Sunny Joseph Barkats, Founding Partner at JS Barkats. "Amarantus' corporate awareness programs, through its #C4CT concussion program and emerging relationships with professional athletes, are pioneering within development-stage biotechnology that will allow the Company to carve out a unique position for itself in the marketplace as it executes on its business strategy
Amarantus has developed over 80 PhenoGaurd cell lines to date, and has utilized their PhenoGaurd Protein
Discovery Engine to identify MANF as a potential breakthrough therapy for neurological disorders and
cardiac disease.
Animal and human studies confirm that MANF is a
biological protein that is produced in the body to establish and maintain the nervous system. Furthermore,
studies have shown that MANF is also highly produced during times of cardiac stress, indicating that this
protein plays a crucial role in heart health.
MANF (AMRS001) was discovered studying Amarantus’ first established cell line of neurons. It was found to
have a striking ability to save neurons from cell death when disease conditions were presented. This was a
remarkable finding in regard to therapeutic potential, as neuron cell death is the underlying cause of
neurologic conditions such as Parkinson’s disease
HEART DISEASE positive research data
http://ih.advfn.com/p.php?pid=nmona&article=54308207
Brewer Sports International (BSI), a globally diversified boutique services provider for professional athletes, sports agencies and numerous other international organizations touching the sports and wellness field, today announced the launch of a new movement called the “Coalition for Concussion Treatment”. Referred by the twitter shorthand #C4CT, the purpose of the coalition is to continue building awareness about key scientific and medical advances in an ongoing effort to identify and develop new Traumatic Brain Injury (TBI) treatment opportunities.
The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders
This is why Football players are showing support
No neurotrophic factor other than MANF has demonstrated efficacy in the neurorestoration behavioural 6-OHDA model of Parkinson's disease when delivered to the substantia nigra, so this makes today's result very significant. We are currently working to complete the analysis of histology data to confirm that it is in fact dopaminergic re-innervation of the striatum that is responsible for the results reported today. We expect to release the final results, including histology, to the public when the final data package is assembled in the next few months, and we will submit the final study report and manuscript for publication to a peer-reviewed scientific journal jointly with our academic collaborators and study sponsors at the same time. If the histology data confirm the mechanism underlying the behavioural results reported today, the biology causing today's result would represent a major scientific achievement that could lead to a medical breakthrough in treating Parkinson's disease."
The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
SUNNYVALE, Calif. – October 19, 2012 – Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centred on its proprietary anti-apoptotis therapeutic protein MANF, today announced that it has appointed Clinton O. Allen to its Advisory Board. Mr. Allen will work with management at Amarantus to improve internal controls, prepare due diligence materials for investors and implement corporate governance best practices.
“Clinton Allen is a seasoned biopharmaceutical executive with exceptional leadership capabilities and experience in Big Pharma,” said Gerald E. Commissiong, President & CEO of Amarantus. “He will be a tremendous asset for the Company as we execute on our corporate strategy
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development. Mr. Allen was a captain in the United States Army and received his master in in Environmental Management & Sciences from Tufts University.
“I am very excited to join Amarantus at this critical time in its growth cycle,” said Clinton O. Allen, newly appointed advisor to Amarantus. “The team at Amarantus has been working tremendously hard over the last few years to bring the MANF Program closer to actualizing its true potential. Now that the Company is looking at various partnering and funding opportunities to drive shareholder value, it is an opportune time to join the team in order to meticulously evaluate proposals and make recommendations for future
Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack
Rationale to follow Amarantus: Currently, available treatments for degenerative neurological disorders
such as Parkinson’s disease only alleviate patient symptoms, and do not function to reverse or stop disease
progression. Therefore, there is a critical need for curative therapies that can impede the deterioration of the
nervous system, which is the root cause of these neurological conditions. Amarantus BioSciences [OTC BB:
AMBS] is pioneering the development of a novel therapeutic protein that has neuron-protective properties –
termed MANF – which has the potential to serve as a first-in-class treatment for neurological disorders that
stops and/or reverses their debilitating effects. Importantly, MANF is also significantly cardiac-protective,
providing Amarantus the ability to employ a two pronged drug development approach – a neurological
disorder platform, and a heart disease platform.
I think we see .05 today!
Wow ....looking good...had to go get gas for generator
$AMBS fast forward to 4:13 to listen about what the Company's plans are with their IP(intellectual portfolio) one of them being Manf
I would hold on.....most likely Amarantus will partner with a large Biotech which will benefit us all substantially and then that is only the tip of the iceberg.....They have No intentions on bringing this through FDA approval on their own --but just the rights to the molecular protein is worth 30 million plus ( and that's being conservative)That should put our PPS from .10 to .30!
The news could come out at any time also of a Letter of Intent
http://ih.advfn.com/videos/stock-research/amarantus-biosciences-interviewed-on-the-big-biz-radio-show_nseWcV4uvO8
They own rights to a Protein which reverses CELL DEATH. This Protein (MANF) has Many Many other uses for other diseases in the future but they first started with Parkinson's most Likely b/c of the Michael j. Fox Foundation Funding them in the beginning.
The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders
The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders
The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders
The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
"Today's announcement is transformational for Amarantus from a scientific data standpoint," said Gerald E. Commissiong, President & CEO of Amarantus. "Despite the many clear scientific advantages we believe MANF possesses over GDNF, most notably impacting protein folding and modulating toxic calcium levels, the Company had previously been unable to point to a definitive behavioural animal model data to show improved benefit of MANF over GDNF in the Parkinson's disease indication. The data we now have validates the approach we have been taking over the last several years, and we believe that it will allow us to attract the interest of investment firms and potential partners who will be able to now characterize the substantial opportunity our technology represents. We believe that we are well positioned to leverage the MANF opportunity for Amarantus shareholders and Parkinson's patients because of the expansive intellectual property (IP) portfolio the Company owns, including composition of matter patents in the US and Europe, use patents worldwide and provisional delivery dosing patents that have been filed based on today's data, extending marketing exclusivity for MANF through 2031. This IP position may make MANF more attractive to a potential partner than other neurotrophic factors in development that do not have the same patent runway."
No neurotrophic factor other than MANF has demonstrated efficacy in the neurorestoration behavioural 6-OHDA model of Parkinson's disease when delivered to the substantia nigra, so this makes today's result very significant. We are currently working to complete the analysis of histology data to confirm that it is in fact dopaminergic re-innervation of the striatum that is responsible for the results reported today. We expect to release the final results, including histology, to the public when the final data package is assembled in the next few months, and we will submit the final study report and manuscript for publication to a peer-reviewed scientific journal jointly with our academic collaborators and study sponsors at the same time. If the histology data confirm the mechanism underlying the behavioural results reported today, the biology causing today's result would represent a major scientific achievement that could lead to a medical breakthrough in treating Parkinson's disease."
Neurotrophic factors have been promising drug candidates for Parkinson's disease for over two decades because they have special biological properties that allow them to selectively protect certain neurons. Large biotechnology companies and leading academic investigators have conducted a number of clinical trials on GDNF in Parkinson's disease first initiated in 1996, at an estimated total cost of over $400M, where GDNF has shown promise as a disease-modifying treatment. However, technological limitations of delivering neurotrophic factors to the brain, limitations that Amarantus believes have been resolved by researchers in academia and industry, have delayed the translation of the underlying biology of neurotrophic factors into approved medicines. A unique drug such as MANF that potentially acts by re-innervating the striatum when delivered to the substantia nigra, combined with newly improved delivery technologies capable of getting MANF to the substantia nigra, could complement or replace drugs in development that may get to market ahead of MANF, especially in later-stage patients.
Its going to be a fun ride!
True....but i don't think this went pop just because of him buying in....they have already spent 30 million on their IP portfolio (intellectual property) and him buying in just added icing to the cake......we can assume many things but I see the true value of this company and what they have in their arsenal. Still way undervalued company.I love how they have a partnering strategy to bring their works to fruition.
Do some DD before posting please
I would hate be empty handed with no Ambs shares when it comes out.....I would regret it for a long time
Why would a former Bristol Myers Squibb director join the company
Why would he agree to pay a premium price and they have to file it? It was at. 0062 then....he payed. 01. Something more behind this ....something
Your welcome....I have been here since. 005 and have done many hrs. Of research on this Co. And all I see is positive things. If I didn't truly believe in this technology I wouldn't still be here. I just have a feeling this is going to keep going because the potential is there and right now with just their patents alone ....their market cap. Should be around 30 million. This ishas been off the radar for a year since going public ....now that all the pieces of the puzzle are coming together we are going to see the light and many people will benefit financially and when brought to commercialization ....physically and emotionally....Michael j. Fox being one of them.
If everyone watched the videos.....they would realize the real potential here. They are a Co. Interested in partnering up with major biotech Companies to bring their breakthrough technology through the FDA approval process. They will have many partners to pick up all the expenses of going through FDA approval which is very costly. Many of their research reports performed by independant labs have reported all positive results . The most significant of recent was proving Manf was proven superior to another drug (Gndf) in which major biotechs have spent over 400 million to develop. If a major biotech spends that much to develop an inferior drug to Manf...I feel Amarantus is in the drivers seat when it comes to negotiating a price.What that price is ....is anyone's guess at this point. The most exciting thing is that just because they agree to a price for it for the cure for Parkinson with one company is that they still own the rights for it to sell to another company for heart disease! This protein MANF reverses cell death which is what happens with most if not all diseases......the possibilities are limitless. It seams too good to be true but it is time for the biotech industry to start earning what they are payed for......the biotech industry is coming to pharmageddon.
I am grateful to be a part of the beginning of the end of biotechs as we have known them...
Am I being a bit too optimistic...the research speaks for itself......now its time to do yours
Good luck to you all......now lets make some $$$
Your welcome
Your welcome